Replies to post #3162 on BioCurex, Inc.(fka BOCX)

[erthang]

Kag - there is no doubt that Biocurex has retained all rights to the technology. The wording of the licensing agreement with Abbott in the press release did not have detailed info. That is why there is need for a non-disclosure agreement. I'm pretty sure Abbott only has semi-exclusive rights to the diagnostics side, and even that may be limited to specific cancer types. We don't know. I don't think it would be very intelligent of Dr. Moro to allow any company to have rights to all applications of the technology! Besides, Dr. Moro stated in the interview that he was going to keep the therapeutic side of the recaf technology within the company! Remember, when we talk about recaf technology, we are talking apples, oranges and bananas, depending on what application is being discussed.

[bocxman]

Kag, to add further confusion...the 10-K (annual report), which is as official as it gets, states that BOCX has retained the rights to the RIA ("home brew") application but doesn't mention histo-recaf, imaging, etc. Also, in conversations with management I have been told that they retained the rights to the therapy indication.

I'm pretty sure that Abbott licensed serum-RECAF alone.